EMA/PE/0000241527

Opinion/decision on a Paediatric investigation plan (PIP): Yorvipath, palopegteriparatide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrine disorders, PIP number: EMA/PE/0000241327

EMA/PE/0000238807

EMA/PE/0000232780

EMA/PE/0000231576

EMA/PE/0000240469

Opinion/decision on a Paediatric investigation plan (PIP): Briviact (in Italy: Nubriveo), Brivaracetam, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders, PIP number: EMA/PE/0000240232

Opinion/decision on a Paediatric investigation plan (PIP): Juluca, rilpivirine hydrochloride,dolutegravir sodium, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: EMA/PE/0000240971

Human medicines European public assessment report (EPAR): Telmisartan Actavis, telmisartan, Date of authorisation: 29/09/2010, Revision: 16, Status: Authorised

EMA workshop on the challenges in drug development, regulation and clinical practice in immune thrombocytopenia, Online, from 30 June 2026, 14:00 (CEST) to 30 June 2026, 18:00 (CEST)